Hemodynamics and Hepatic Energy Metabolism in Canine Model of Acute Hepatic Venous Occlusion with Mesocaval Shunt

Terasaki, Mitsuhiro; Kitai, Toshiyuki; Morimoto, T.; Kumada, Kaoru; Sasaki, Hiroyoshi; Nakano, Masahiko; Sugano, Masayuki; Nishizawa, F; Mashima, Susumu; Mitsuyoshi, Akira; Nakagami, Mikio; Takeuchi, E; Ozawa, K.

doi:10.1159/000129314

Cited by 11 publications

(5 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Progressive fibrosis, nodular regenerative hyperplasia and cirrhosis develop during the course of disease [22] . Interventional portosystemic shunts or development of portal venous collateral system may improve liver functions and delay the cirrhotic process [23] .…”

Section: Pathogenesismentioning

confidence: 99%

Budd-Chiari syndrome: Etiology, pathogenesis and diagnosis

Aydınlı

Bayraktar

2007

WJG

161

127

View full text Add to dashboard Cite

Budd-Chiari syndrome is a congestive hepatopathy caused by blockage of hepatic veins. This syndrome occurs in 1/100000 in the general population. Hypercoagulable state could be identified in 75% of the patients; more than one etiologic factor may play a role in 25% of the patients. Primary myeloproliferative diseases are the leading cause of the disease. Two of the hepatic veins must be blocked for clinically evident disease. Liver congestion and hypoxic damage of hepatocytes eventually result in predominantly centrilobular fibrosis. Doppler ultrasonography of the liver should be the initial diagnostic procedure. Hepatic venography is the reference procedure if required. Additionally liver biopsy may be helpful for differential diagnosis. The prognosis of the chronic form is acceptable compared to other chronic liver diseases.

show abstract

Section: Pathogenesismentioning

confidence: 99%

Budd-Chiari syndrome: Etiology, pathogenesis and diagnosis

Aydınlı

Bayraktar

2007

WJG

161

127

View full text Add to dashboard Cite

show abstract

“…In canine models, maintenance of portal pressure by shunt creation after hepatic venous occlusion results in preservation of hepatic energy metabolism and hepatic function. 93 The role of the TIPS procedure in the management of advanced stages of VOD remains undefined. Isolated case reports and small case series have shown benefit in a few patients, especially those with less advanced disease.…”

Section: Therapymentioning

confidence: 99%

Hepatic Veno-occlusive Disease (Sinusoidal Obstruction Syndrome) After Hematopoietic Stem Cell Transplantation

Kumar

DeLeve

Kamath

et al. 2003

Mayo Clinic Proceedings

189

145

View full text Add to dashboard Cite

Hepatic veno-occlusive disease (VOD), increasingly referred to as sinusoidal obstruction syndrome, is a well-recognized complication of hematopoietic stem cell transplantation and contributes to considerable morbidity and mortality. In the Western Hemisphere, VOD, classified as a conditioning-related toxicity, is most commonly caused by stem cell transplantation. VOD has been described after all types of stem cell transplantation, irrespective of the stem cell source, type of conditioning therapy, or underlying disease. Recognition of this disease in the posttransplantation setting remains a challenge in the absence of specific diagnostic features because many other more common conditions can mimic it. Limited therapeutic or preventive strategies are currently available for the management of VOD. In this review, we provide a comprehensive account of the pathophysiology of this disease as we understand it today, risk factors for its development, and the current state of knowledge regarding preventive and therapeutic options.

show abstract

“…Sixty-nine pertinent articles were retrieved and included in the present study, including 32 reviews [ 1 - 4 , 6 - 33 ], 32 retrospective [ 34 - 64 ], four prospective [ 65 - 68 ], and one experimental studies [ 5 ] ( Fig. 1 ).…”

Section: Resultsmentioning

confidence: 99%

“…If the condition remains under-recognized and the obstruction is not corrected in a timely manner, this can lead to hepatocyte necrosis, progressive centrilobular fibrosis, nodular regenerative hyperplasia, and ultimately cirrhosis [ 1 - 4 ]. Therefore, if the hepatic flow is restored either by development of the portal venous collateral system or by creation of a portosystemic shunt, the hepatic sinusoidal pressure will be reduced drastically [ 5 ]. Thus, treatment strategies should be based on detailed knowledge of the underlying etiological factors, clinical presentation, and baseline liver function.…”

Section: Introductionmentioning

confidence: 99%

State of the Art, Current Perspectives, and Controversies of Budd-Chiari Syndrome: A Review

et al. 2022

View full text Add to dashboard Cite

Background Budd-Chiari syndrome (BCS) is an eponym that includes a group of conditions characterized by partial or complete hepatic venous tract outflow obstruction, and the site of obstruction may involve one or more hepatic veins, inferior vena cava, or the right atrium. The classification of BCS is based on etiology, site of obstruction, and duration. Its etiology is very heterogeneous; in particular, hepatic vein thrombosis is the most common type of obstruction and myeloproliferative disorder, the most common thrombophilic disorder, in the West. In Asian countries, the type of obstruction, thrombophilic disorders, clinical features, and treatment strategies vary widely from region to region. Although the cause can be identified in 90% of patients with the help of gene mutation testing, BCS remains under-recognized in many countries. A higher prevalence of acute cases has been reported in the West than in the East. This global and regional heterogeneity raises several challenges regarding the evaluation, management strategy, and individualized approach of BCS. This study aimed to conduct a systematic review of BCS to elucidate treatment strategy options. Methods PubMed, Embase, Cochrane Library, and Google Scholar databases were searched systematically. Results Sixty-nine pertinent articles were retrieved and included in the present study. Conclusions Further research on the following three topics would help define individualized treatment strategies. The first is a better understanding of the molecular pathways underlying the thrombophilic conditions implicated in the pathogenesis of BCS. The second is the role of the genotype and gene mutations in the determination of coagulation status of patients with BCS. The third is the definition of clear criteria and development of a common prognostic index to risk stratify the patients at presentation and consequently detect candidates for invasive therapies.

show abstract

Hemodynamics and Hepatic Energy Metabolism in Canine Model of Acute Hepatic Venous Occlusion with Mesocaval Shunt

Cited by 11 publications

References 10 publications

Budd-Chiari syndrome: Etiology, pathogenesis and diagnosis

Budd-Chiari syndrome: Etiology, pathogenesis and diagnosis

Hepatic Veno-occlusive Disease (Sinusoidal Obstruction Syndrome) After Hematopoietic Stem Cell Transplantation

State of the Art, Current Perspectives, and Controversies of Budd-Chiari Syndrome: A Review

Contact Info

Product

Resources

About